Equities research analysts expect OptimizeRx Co. (NASDAQ:OPRX) to announce sales of $6.78 million for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for OptimizeRx’s earnings. The highest sales estimate is $6.88 million and the lowest is $6.63 million. OptimizeRx posted sales of $5.10 million in the same quarter last year, which suggests a positive year-over-year growth rate of 32.9%. The firm is scheduled to announce its next earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that OptimizeRx will report full year sales of $28.70 million for the current fiscal year, with estimates ranging from $28.45 million to $28.85 million. For the next financial year, analysts forecast that the firm will post sales of $37.79 million, with estimates ranging from $37.17 million to $38.41 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for OptimizeRx.

Separately, Zacks Investment Research raised OptimizeRx from a “hold” rating to a “strong-buy” rating and set a $16.00 price objective for the company in a research report on Tuesday, May 14th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $19.00.

NASDAQ OPRX traded down $0.18 on Tuesday, hitting $14.70. The company’s stock had a trading volume of 70,100 shares, compared to its average volume of 67,616. The firm has a market capitalization of $178.27 million, a price-to-earnings ratio of 294.00, a P/E/G ratio of 1.70 and a beta of 0.50. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.02 and a current ratio of 4.02. The firm’s 50-day simple moving average is $14.53. OptimizeRx has a 52-week low of $8.92 and a 52-week high of $18.39.

In other news, major shareholder Awm Investment Company, Inc. sold 82,126 shares of the business’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $13.64, for a total value of $1,120,198.64. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

A number of hedge funds and other institutional investors have recently modified their holdings of OPRX. BlackRock Inc. acquired a new stake in OptimizeRx during the 4th quarter valued at $55,000. Westwood Management Corp IL bought a new stake in OptimizeRx in the 1st quarter valued at about $127,000. Bank of America Corp DE increased its stake in OptimizeRx by 15.8% during the 4th quarter. Bank of America Corp DE now owns 15,302 shares of the company’s stock valued at $168,000 after buying an additional 2,084 shares during the period. Northern Trust Corp increased its stake in OptimizeRx by 71.5% during the 4th quarter. Northern Trust Corp now owns 17,474 shares of the company’s stock valued at $192,000 after buying an additional 7,283 shares during the period. Finally, Alambic Investment Management L.P. acquired a new position in OptimizeRx during the 4th quarter valued at about $289,000. 48.47% of the stock is currently owned by institutional investors.

About OptimizeRx

OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.

Further Reading: What is Cost of Debt?

Get a free copy of the Zacks research report on OptimizeRx (OPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OptimizeRx (NASDAQ:OPRX)

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.